This is encouraging early clinical data but from only a handful of patients without reported statistics. The stock may react positively on the survival and recovery signals, but de-risking is marginal until larger randomized data drop in early 2027. Expect volatility; consider positioning for the next data readout rather than chasing the initial pop.
Drug in focus
INKT drug pipeline →agenT-797
● Neutral Named in this press release- Impact
- Phase
- Phase 2
- Time to market
- agenT-797 is not approved in any market. The most advanced program is the randomized Phase 2 ARDS trial (C-1300-02), with data expected in 2H2027. Even with positive data, additional trials and regulatory review would be needed before any potential approval, likely several years away.
- Next catalyst
- None dated
What to watchThe next hard catalyst is the U.S. dosing initiation in the randomized Phase 2 ARDS trial (C-1300-02), expected before year-end 2026, with topline data not expected until 2H2027. In the nearer term, watch for any updates on the ARPA-H BoSS program funding allocation and enrollment progress in the ongoing Phase 2 colorectal cancer trial. The company's $7.5M cash position and $1.3M quarterly operating burn suggest a financing event may be needed within 2-3 quarters to fund the ARDS trial through readout.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 6 $11.00entry
- T+1 · 3mo ago −0.45%α −1.07% · $10.95
- T+5 · 3mo ago 0.00%α −1.21% · $11.00
- T+20 · 3mo ago +2.09%α +1.49% · $11.23
- T+60 · 18d ago −4.27%α −2.60% · $10.53
Price Chart
How similar events traded
Executive Summary
MiNK Therapeutics presented initial Phase 2 data at MHSRS showing first patients treated with agenT-797 for severe hypoxemic pneumonia were alive and afebrile at Day 28 with improved oxygenation, infection control, and removal from ventilator/vasopressor support. Biological signals included reduced inflammation and increased tissue repair markers. Enrollment continues in Ukraine with U.S. sites opening; additional data expected in early 2027. For a $58M market cap company, these early observations are positive but not statistically significant given tiny patient numbers and no placebo comparison yet.
Key Facts
- First patients treated with agenT-797 were alive and afebrile at Day 28 with improved oxygenation and infection control.
- Patients removed from ventilator and vasopressor support.
- No major serious adverse events attributed to agenT-797 reported in these first treated patients.
- Biological changes associated with immune recovery, epithelial repair, and pulmonary vascular recovery observed.
- Randomized Phase 2 trial (C-1300-02) ongoing in Lviv, Ukraine; U.S. sites opening.
- Additional data expected in early 2027.
- agenT-797 is off-the-shelf, no apheresis, patient-specific manufacturing, HLA matching, or lymphodepletion required.
- MiNK has a $58M market cap.
Financial Impact
Not disclosed in press release; no financial data provided.
Risk Factors
- Very early-stage data from few patients, not statistically significant.
- Placebo-controlled arm not reported yet; high risk of no benefit in randomized portion.
- Next major data not expected until early 2027, long wait with no near-term catalyst.
- Clinical-stage biotech with no approved products or revenue, binary outcome risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3340551 |
Track record
21 reports on INKT
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +16.93% at T+20 after the May 15, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 4/10 Entry $10.22 Now $9.35 −8.55% settles Dec 10
- Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
- Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
- Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
- Aug 13, 202613w ago 8-K Mixed 6/10 No price data
- Aug 13, 202613w ago Press Release Mixed 6/10 Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
- Aug 6, 202614w ago Press Release Bullish 6/10 Viewing Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
- May 28, 202624w ago Press Release Neutral 4/10 Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
- May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers